Report Library
All ReportsDatamonitor Healthcare Oncology: Prostate Cancer Pricing & Reimbursement
June 01, 2018
Interviewed payers in the US and five major EU markets (France, Germany, Italy, Spain and the UK) express concern surrounding the
significant and rising cost of prostate cancer treatment. Payers highlight the large and growing epidemiology of the disease, as well as the
rising costs associated with the use of expensive novel anti-androgens in earlier treatment lines.
This Datamonitor Healthcare report contains a Pricing & Reimbursement module.
This Datamonitor Healthcare report contains a Pricing & Reimbursement module.
Indications Covered: | Prostate Cancer |